Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

18F FSPG

Next Previous
Drug Profile

18F FSPG

Alternative Names: 18F-FSPG; BAY94-9392; FSPG

Latest Information Update: 19 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Life Molecular Imaging; National Cancer Institute (USA); Stanford University
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cancer; Inflammation; Inflammatory bowel diseases
  • No development reported Brain cancer

Most Recent Events

  • 19 Aug 2025 M.D. Anderson Cancer Center plans a phase I trial for Liver cancer (Diagnosis) in USA (IV) in December 2025 (NCT07116486)
  • 07 Apr 2023 Stanford University in collaboration with GE Healthcare terminates a phase II trial Inflammation (Diagnosis) in USA (IV) due to loss of funding (NCT03103490)
  • 03 Nov 2021 Phase II development is still ongoing for Cancer (Diagnosis) in USA (Life Molecular Imaging website, October 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top